JP Morgan Maintains Overweight on Pliant Therapeutics, Raises Price Target to $48
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Eric Joseph maintains an Overweight rating on Pliant Therapeutics (NASDAQ:PLRX) and raises the price target from $47 to $48.
August 10, 2023 | 4:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Pliant Therapeutics and raises the price target from $47 to $48, indicating positive sentiment.
The raised price target by JP Morgan indicates a positive outlook for Pliant Therapeutics. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100